BiotechTube
Home/ITB Med/Matthew Lamb
ML

Matthew Lamb

Chief Executive Officer (Interim)

ITB Med

Therapeutic Areas

TransplantationAutoimmunity

ITB Med Pipeline

DrugIndicationPhase
TCD601 for Kidney ToleranceKidney TransplantationPhase 2
TCD601 for Kidney InductionKidney TransplantationPhase 2
TCD601 for Type-1 DiabetesType-1 Diabetes (New-onset remission)Phase 2
TCD601 for ALSAmyotrophic Lateral SclerosisPhase 2
TCD601 for Liver ToleranceLiver Transplantation (non-autoimmune)Phase 1
TCD601 for GVHD PreventionBone Marrow TransplantationPhase 1

Leadership Team at ITB Med

LZ
Leslie Zacks
Chief Legal and Compliance Officer
KG
Kasper Granlund
Chief Financial Officer
KC
Kellie Calderon
Vice President, Medical Strategy
View full ITB Med profile